Camurus AB Cash Flow Conversion Efficiency
Camurus AB cash flow conversion efficiency. Based on the latest financial reports, Camurus AB (CAMX) has a cash flow conversion efficiency ratio of 0.060x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr255.43 Million ≈ $27.49 Million USD) by net assets (Skr4.24 Billion ≈ $455.80 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Camurus AB (2012–2025)
Cash flow conversion efficiency of Camurus AB from 2012 to 2025. This chart illustrates how Camurus AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Camurus AB share price for real-time trading data and today's change.
Camurus AB Cash Flow Conversion Ratio Explained
Camurus AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Camurus AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Camurus AB ranked by their cash flow conversion efficiency. Also see market value of Camurus AB for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
D-Wave Quantum Inc.
NYSE:QBTS
|
-0.040x |
|
Bank Handlowy w Warszawie SA
WAR:BHW
|
-0.309x |
|
Flughafen Wien Aktiengesellschaft
VI:FLU
|
0.039x |
|
Enova International Inc
NYSE:ENVA
|
0.363x |
|
Shanghai Lujiazui Finance & Trade Zone Development Co Ltd A
SHG:600663
|
0.058x |
|
Grupo Aeroportuario del Centro Norte S.A.B. de C.V.
F:G7A
|
0.137x |
|
Bidvest Group Ltd
JSE:BVT
|
0.172x |
|
Cinemark Holdings Inc
NYSE:CNK
|
0.174x |
Annual Cash Flow Conversion Efficiency for Camurus AB (2012–2025)
The table below shows the annual cash flow conversion efficiency of Camurus AB from 2012 to 2025. Review Camurus AB (CAMX) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr4.24 Billion ≈ $455.80 Million |
Skr869.30 Million ≈ $93.55 Million |
0.205x | +74.02% |
| 2024-12-31 | Skr3.29 Billion ≈ $354.02 Million |
Skr387.99 Million ≈ $41.75 Million |
0.118x | -70.98% |
| 2023-12-31 | Skr1.49 Billion ≈ $160.67 Million |
Skr606.88 Million ≈ $65.31 Million |
0.406x | +299.53% |
| 2022-12-31 | Skr994.67 Million ≈ $107.04 Million |
Skr101.20 Million ≈ $10.89 Million |
0.102x | +160.22% |
| 2021-12-31 | Skr848.91 Million ≈ $91.36 Million |
Skr-143.43 Million ≈ $-15.44 Million |
-0.169x | +40.05% |
| 2020-12-31 | Skr847.44 Million ≈ $91.20 Million |
Skr-238.83 Million ≈ $-25.70 Million |
-0.282x | +55.98% |
| 2019-12-31 | Skr631.63 Million ≈ $67.97 Million |
Skr-404.36 Million ≈ $-43.52 Million |
-0.640x | +41.06% |
| 2018-12-31 | Skr252.32 Million ≈ $27.15 Million |
Skr-274.08 Million ≈ $-29.50 Million |
-1.086x | -105.94% |
| 2017-12-31 | Skr385.00 Million ≈ $41.43 Million |
Skr-203.07 Million ≈ $-21.85 Million |
-0.527x | -43.27% |
| 2016-12-31 | Skr564.42 Million ≈ $60.74 Million |
Skr-207.79 Million ≈ $-22.36 Million |
-0.368x | -4068.62% |
| 2015-12-31 | Skr640.56 Million ≈ $68.93 Million |
Skr-5.66 Million ≈ $-608.78K |
-0.009x | -101.57% |
| 2014-12-31 | Skr123.46 Million ≈ $13.29 Million |
Skr69.43 Million ≈ $7.47 Million |
0.562x | -82.74% |
| 2013-12-31 | Skr50.05 Million ≈ $5.39 Million |
Skr163.06 Million ≈ $17.55 Million |
3.258x | +429.67% |
| 2012-12-31 | Skr40.21 Million ≈ $4.33 Million |
Skr24.73 Million ≈ $2.66 Million |
0.615x | -- |
About Camurus AB
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029… Read more